At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 61 enrolled
Drug / intervention
Vitamin D3 +2 moredrug
Likely dose
Vitamin D3 1000 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Comparative Trial of Calcitriol Versus Placebo for the Preservation of Bone Mass and Strength After Kidney Transplantation
In Brief
A Phase 2 clinical trial evaluating Vitamin D3, Calcitriol, and 1 other intervention for End Stage Renal Disease and 4 related conditions. Completed, enrolled 61 participants across 1 site.
Detailed Summary
The purpose of this study is to test whether active vitamin D (calcitriol) protects bones from weakening and protects blood vessels from calcium deposits over the first year of kidney transplantation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnd Stage Renal Disease, Kidney Transplantation, Bone Loss, Fractures, Vascular Calcifications
CountriesUnited States
CollaboratorsSatellite Healthcare
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartAug 2014
First PostedAug 2014
Primary CompletionOct 2016
TodayJul 2026
First PostedAug 25, 2014
Enrollment StartAug 18, 2014
Primary CompletionOct 12, 2016
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 11.9 years ago
Interventions
Vitamin D3drug
Vitamin D3 1000 IU per day for 12 months
Calcitrioldrug
Calcitriol (Rocaltrol) 0.5 mcg per day for 12 months
Placebodrug
Placebo (sugar pill) 1 pill per day for 12 months